The Antithrombotic Effect of Recombinant Neorudin on Thrombi

References

• Germain M, Chasman DI, de Haan H, et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet. 2015;96(4):532–542. doi:10.1016/j.ajhg.2015.01.019
   PubMed Web of Science ®Google Scholar
• Weitz JI, Wood AJJ. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688–698. doi:10.1056/NEJM199709043371007
   PubMed Web of Science ®Google Scholar
• Pineo GF, Hull RD. Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. Baillieres Clin Haematol. 1998;11(3):621–637. doi:10.1016/s0950-3536(98)80086-3
   PubMed Web of Science ®Google Scholar
• Nafee T, Aslam A, Chi G, et al. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Rev Cardiovasc Ther. 2017;15(4):237–245. doi:10.1080/14779072.2017.1305889
   PubMed Web of Science ®Google Scholar
• Amato B, Compagna R, Rocca A, et al. Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. Drug Des Devel Ther. 2016;10:2041–2046. doi:10.2147/DDDT.S106153
   PubMed Web of Science ®Google Scholar
• Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation. 2001;103(10):1479–1484. doi:10.1161/01.cir.103.10.1479
   PubMed Web of Science ®Google Scholar
• Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994;74(1):1–23. doi:10.1016/0049-3848(94)90032-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Lan N. Hirudin variants production by genetic engineered microbial factory. Biotechnol Genet Eng Rev. 2018;34(2):261–280. doi:10.1080/02648725.2018.1506898
   PubMed Web of Science ®Google Scholar
• Fox KA. r-Hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Eur Heart J. 1995;16(Suppl D):28–32. doi:10.1093/eurheartj/16.suppl_d.28
   PubMed Web of Science ®Google Scholar
• Klingele M, Enkel J, Speer T, Bomberg H, Baerens L, Schäfers HJ. Bleeding complications after cardiac surgery, before anticoagulation start and then with argatroban or heparin in the early postoperative setting. J Cardiothorac Surg. 2020;15(1):27. doi:10.1186/s13019-020-1059-8
   PubMed Web of Science ®Google Scholar
• Mahat KC, Sedhai YR, Krishnan P. Argatroban. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 32310431.
   Google Scholar
• Ajmal M, Friedman J, Sipra QUAR, Lassar T, Garcia V. Rivaroxaban: expanded role in cardiovascular disease management-a literature review. Cardiovasc Ther. 2021;2021:8886210. doi:10.1155/2021/8886210
   PubMed Web of Science ®Google Scholar
• Fitchett DH. Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther. 2012;6:349–357. doi:10.2147/DDDT.S30342
   PubMed Web of Science ®Google Scholar
• Wu Z, Guo Y, Liu Y, et al. Production technology of recombinant neorudin expressed in E. coli. Beijing Univ Technol. 2016;42:302–308.
   Google Scholar
• Wu Z, Yu A, Zhang C, et al. Preparation of low bleeding anticoagulant fusion protein and its use. US Patent 20100113345A1. PCT No. PCT/CN2007/ 03526. WO 2008/071081 A1. Filed December 11, 2007; issued Jan 24, 2012.
   Google Scholar
• Zhang C, Yu A, Yuan B, et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk. Thromb Haemost. 2008;99(2):324–330. doi:10.1160/TH07-07-0453
   PubMed Web of Science ®Google Scholar
• Sheffield WP, Eltringham-Smith LJ, Bhakta V. A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss. BMC Biotechnol. 2018;18(1):21. doi:10.1186/s12896-018-0431-4
   PubMed Web of Science ®Google Scholar
• Dong X, Meng Z, Gu R, et al. Predicting the metabolic characteristics of neorudin, a novel anticoagulant fusion protein, in patients with deep vein thrombosis. Thromb Res. 2020;194:121–134. doi:10.1016/j.thromres.2020.05.048
   PubMed Web of Science ®Google Scholar
• Fareed J, Walenga JM, Iyer L, Hoppensteadt D, Pifarre R. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Blood Coagul Fibrinolysis. 1991;2(1):135–147. doi:10.1097/00001721-199102000-00021
   PubMed Web of Science ®Google Scholar
• Sachs UJ, Nieswandt B. In vivo thrombus formation in murine models. Circ Res. 2007;100(7):979–991. doi:10.1161/01.RES.0000261936.85776.5f
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74(5):1361–1367. PMID: 8607123. doi:10.1055/s-0038-1649940
   PubMed Web of Science ®Google Scholar
• Rosen ED, Raymond S, Zollman A, et al. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol. 2001;158(5):1613–1622. doi:10.1016/S0002-9440(10)64117-X
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Umemura K, Kondo K, Saniabadi AR, Nakashima M. Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening. Arterioscler Thromb Vasc Biol. 1998;18(7):1069–1078. doi:10.1161/01.atv.18.7.1069
   PubMed Web of Science ®Google Scholar
• Huttinger AL, Wheeler DG, Gnyawali S, et al. Ferric chloride-induced canine carotid artery thrombosis: a large animal model of vascular injury. J Vis Exp. 2018;(139):57981. doi:10.3791/57981
   PubMed Web of Science ®Google Scholar
• Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Thromb Haemost. 1997;77(6):1143–1147. [ PMID: 9241747]. doi:10.1055/s-0038-1656127
   PubMed Web of Science ®Google Scholar
• Valentin JP, Vieu S, Bertolino F, Fauré P, John GW. Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits. J Pharmacol Exp Ther. 1997;280(2):761–769. PMID: 9023289.
   PubMed Web of Science ®Google Scholar
• Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6(222):222ra17. doi:10.1126/scitranslmed.3006804
   PubMed Web of Science ®Google Scholar
• May F, Krupka J, Fries M, et al. FXIIa inhibitor rHA-Infestin-4: safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis. Br J Haematol. 2016;173(5):769–778. doi:10.1111/bjh.13990
   PubMed Web of Science ®Google Scholar
• Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM. Nonpeptide factor Xa inhibitors: i. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther. 2000;292(1):351–357. PMID: 10604970.
   PubMed Web of Science ®Google Scholar
• Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. doi:10.1161/01.str.20.1.84
   PubMed Web of Science ®Google Scholar
• Liu XG, Xu LN. [A rat middle cerebral artery thrombosis model for evaluation of thrombolytic and antithrombotic agents]. Yao Xue Xue Bao. 1995;30(9):662–667. Chinese. PMID: 8701741.
   PubMedGoogle Scholar
• Liu D, Wang H, Zhang Y, Zhang Z. Protective effects of chlorogenic acid on cerebral ischemia/reperfusion injury rats by regulating oxidative stress-related Nrf2 pathway. Drug Des Devel Ther. 2020;14:51–60. doi:10.2147/DDDT.S228751
   PubMed Web of Science ®Google Scholar
• Hou ST, MacManus JP. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol. 2002;221:93–148. doi:10.1016/s0074-7696(02)21011-6
   PubMedGoogle Scholar
• Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol. 2013;26(2):191–202. doi:10.1016/j.beha.2013.07.001
   PubMed Web of Science ®Google Scholar
• Qin XY, Yu AP, Wang WW, et al. The antithrombin activity detection of EH in vitro. China Biotechnol. 2011;31(5):108–112. doi:10.13523/j.cb.20110518
   Google Scholar
• Dong X, Gu R, Zhu X, et al. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics. Eur J Pharm Sci. 2018;121:166–177. doi:10.1016/j.ejps.2018.05.025
   PubMed Web of Science ®Google Scholar
• Wang W, Xu X, Zhao Z, et al. Anti-thrombus activity of a novel anti-thrombus protein EPR- hirudin. Chin Pharm J. 2013;48(2):111–115.
   Google Scholar
• Shinozawa E, Kawamura M. Anti-thrombotic effect of a factor Xa inhibitor TAK-442 in a rabbit model of arteriovenous shunt thrombosis stimulated with tissue factor. BMC Res Notes. 2018;11(1):776. doi:10.1186/s13104-018-3886-4
   PubMedGoogle Scholar
• Karabiyikoglu M, Hua Y, Keep RF, Ennis SR, Xi G. Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow. J Cereb Blood Flow Metab. 2004;24(2):159–166. doi:10.1097/01.WCB.0000100062.36077.84
   PubMed Web of Science ®Google Scholar
• Wu W, Qiu C, Feng X, et al. Protective effect of paeoniflorin on acute cerebral infarction in rats. Curr Pharm Biotechnol. 2020;21(8):702–709. doi:10.2174/1389201021666191224151634
   PubMed Web of Science ®Google Scholar
• Barreto AD, Ford GA, Shen L, et al. Randomized, multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke). Stroke. 2017;48(6):1608–1616. doi:10.1161/STROKEAHA.117.016720
   PubMed Web of Science ®Google Scholar
• Sun Z, Lan X, Li S, Zhao H, Tang Z, Xi Y. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis. Int J Hematol. 2017;106(4):476–483. doi:10.1007/s12185-017-2271-8
   PubMed Web of Science ®Google Scholar
• Liu YX, Cao QM, Ma BC. Pathogens distribution and drug resistance in patients with acute cerebral infarction complicated with diabetes and nosocomial pulmonary infection. BMC Infect Dis. 2019;19(1):603. doi:10.1186/s12879-019-4142-9
   PubMed Web of Science ®Google Scholar
• Liang Y, Wu J, Liu J, Liu H, Chen J. The clinical implications of thrombelastography in the diagnosis of acute cerebral infarction. Clin Lab. 2018;64(1):147–152. doi:10.7754/Clin.Lab.2017.170803
   PubMed Web of Science ®Google Scholar